Eli Lilly Shares Sold by Capital World Investors

Institutional investor reduces stake in pharmaceutical giant

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Capital World Investors, a major institutional investor, has reduced its holdings in Eli Lilly and Company (NYSE: LLY) by 15.1% in the 3rd quarter, according to a recent SEC filing. The firm now owns 14,969,899 shares of the company's stock, down from 17,634,492 shares previously.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, so changes in major institutional ownership can signal broader market trends and investor sentiment around the stock. This reduction by Capital World Investors, a prominent investment firm, may indicate some uncertainty about Eli Lilly's future prospects.

The details

According to the SEC filing, Capital World Investors sold 2,664,593 shares of Eli Lilly during the 3rd quarter. The firm now owns approximately 1.58% of Eli Lilly's outstanding shares, down from 1.86% previously. Eli Lilly makes up about 1.6% of Capital World Investors' overall portfolio.

  • Capital World Investors reduced its Eli Lilly holdings in the 3rd quarter of 2026.

The players

Capital World Investors

A major institutional investment firm that has reduced its stake in pharmaceutical company Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company headquartered in Indianapolis, Indiana that develops and commercializes a range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Capital World Investors' Eli Lilly holdings could signal some broader uncertainty around the pharmaceutical company's future prospects, though the firm still maintains a sizable stake. Investors will likely watch for any further changes in major institutional ownership of Eli Lilly stock.